Prognostic effect of systemic immune-inflammation index (SII) in 987
patients with advanced/metastatic urinary tract carcinoma (mUTC) treated
with atezolizumab in the real-world global SAUL study
Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Έτος δημοσίευσης:
2020
Συγγραφείς:
Mego, M. Huddart, R. A. Voortman, J. Ong, M. Gedye, C. and Gurney, H. Fay, A. P. Bamias, A. Mellado Gonzalez, B. and Loriot, Y. Merseburger, A. S. Castellano Gauna, D. de Ducla, S. Pavlova, J. Fear, S. Sternberg, C. N.
